Pharmaceutical

First targeted alpha therapy wins FDA breakthrough device designation

RadioMedix and Orano Med’s radioligand therapy AlphaMedix (lead-212-Dotamtate) is currently in a Phase II trial.

Feb 12, 2024 - 18:00
First targeted alpha therapy wins FDA breakthrough device designation
RadioMedix and Orano Med’s radioligand therapy AlphaMedix (lead-212-Dotamtate) is currently in a Phase II trial.
Read the original article

Tags:

Previous Article

Disc wins orphan drug tag for rare blood cancer  

Next Article

CSL’s ‘big’ post-heart attack drug fails in Phase III trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AbbVie and Richter partner for neuropsychiatric treatments

AbbVie and Richter partner for neuropsychiatric treatments

Oct 26, 2024

STAT+: Six months after launch, Bert Vogelstein’s latest blood testing startup gets acquired for $450 million

STAT+: Six months after launch, Bert Vogelstein’s lates...

Apr 27, 2023

Shrinking Covid vaccine sales has Moderna course-correcting

Shrinking Covid vaccine sales has Moderna course-correc...

Nov 3, 2023